Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers

Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers

Background: Cannabidiol (CBD) is a cannabinoid of potential interest for the treatment of substance use disorders. Our aim was to review the outcome measures, surrogate endpoints, and biomarkers in published and ongoing randomized clinical trials.Methods: We conducted a search in PubMed, Web of Scie...

Full description

Bibliographic Details
Main Authors: Alix Morel, Pierre Lebard, Alexandra Dereux, Julien Azuar, Frank Questel, Frank Bellivier, Cynthia Marie-Claire, Mélina Fatséas, Florence Vorspan, Vanessa Bloch
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Psychiatry
Subjects:
cannabis
tobacco
opioid
clinical trials
cannabinoids
cannabidiol
Online Access:https://www.frontiersin.org/articles/10.3389/fpsyt.2021.565617/full

Internet

https://www.frontiersin.org/articles/10.3389/fpsyt.2021.565617/full

Similar Items